Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_20_2201 - A Propensity Analysis Comparing Definitive Chemo-Radiation for Muscle-Invasive Adenocarcinoma of the Bladder Versus Urothelial Carcinoma of the Bladder using the National Cancer Database (NCDB)

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

A Propensity Analysis Comparing Definitive Chemo-Radiation for Muscle-Invasive Adenocarcinoma of the Bladder Versus Urothelial Carcinoma of the Bladder using the National Cancer Database (NCDB)
R. Brenneman1, B. W. Fischer-Valuck2, H. A. Gay1, J. Contreras1, V. Arora3, J. P. Christodouleas4, G. L. Andriole5, A. Bullock5, R. Figenshau5, E. Kim5, E. Knoche3, R. Pachynski3, J. Picus3, B. Roth3, J. M. Michalski6, and B. C. Baumann1; 1Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, 2Washington University School of Medicine, Department of Radiation Oncology, St. Louis, MO, 3Department of Medicine, Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, 4Department of Radiation Oncology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, 5Division of Urological Surgery, Washington University School of Medicine, St. Louis, MO, 6Washington University School of Medicine, St. Louis, MO

Purpose/Objective(s): Adenocarcinoma (AC) accounts for <2% of all primary bladder cancers in the Western world. Treatment for localized AC is extrapolated from urothelial carcinoma (UC) results, with limited data on efficacy in AC, particularly for definitive chemo-radiation (CRT). We hypothesized that overall survival (OS) between AC and UC patients treated with definitive CRT would be equivalent.

Materials/Methods: We queried the NCDB for muscle-invasive (cT2-T4 N0-3 M0) bladder cancer patients diagnosed between 2004-2013 treated with concurrent CRT after TURBT. Patients receiving RT doses < 40 Gy were excluded. OS was analyzed using Kaplan-Meier techniques. Univariate and multivariable (MVA) Cox regression and propensity matching (1:1) were performed for demographic, clinical, and treatment variables. P-values <0.05 were considered significant.

Results: A total of 4,760 patients met inclusion criteria with 74 (1.6%) having AC. Median age (years) was 73 (range: 41-89) for AC and 77 (range: 40-90) for UC. Males accounted for 62% of AC patients and 73% of UC patients. AC had higher ≥cT3 disease compared to UC (p= 0.006) but there was no difference in cN- stage (p= 0.79). Median OS (months) was 25.2 (95% CI 18.5-32.0) for AC versus 24.7 (95% CI 23.6-25.9) for UC (p= 0.453). On MVA, age (HR: 1.02, 95% CI 1.01-1.02; p<0.0001), female sex (HR 1.09, 95% CI 1.02-1.18; p= 0.015), higher Charlson-Deyo comorbidity index (HR 1.30, 95% CI 1.28-1.32; p<0.0001), ≥cT3 disease (HR 1.37, 95% CI 1.21-1.51; p= 0.003), and positive nodal status (HR 1.41, 95% CI 1.32-1.56; p= 0.0001) were associated with worse OS. AC histology was not predictive of OS on MVA (p= 0.313). After propensity matching, 73 patients from each histology group were analyzed (n= 146). Median OS (months) for AC was 25.3 (95% CI 19.4-31.2) versus 18.6 (95% CI 14.7-22.4) for UC (p= 0.630). On subset analysis no co-variables (age, race, sex, cT stage, or cN stage) were associated with improved OS.

Conclusion: To our knowledge, this study is the first to compare outcomes with definitive CRT in patients with adenocarcinoma of the bladder vs. urothelial carcinoma of the bladder. OS favored AC but the differences were not significant. While the data is limited by the small sample size, the results suggest that definitive CRT may be a viable option for patients with AC.

Author Disclosure: R. Brenneman: None. B.W. Fischer-Valuck: None. H.A. Gay: None. J.P. Christodouleas: Vice President of Medical Affairs and Clinical Research; Elekta. G.L. Andriole: Consultant; Amgen, Augmenix, GlaxoSmithKline, Janssen Biotech, Inc, Myriad Genetics, Steba Biotech, Bayer. Chief, Division of Urologic Surgery; Washington University School of Medicine. A. Bullock: None. E. Kim: None. E. Knoche: None. B. Roth: None. J.M. Michalski: Independent Contractor; Sheila Michalski and Associates. Research Grant; NCI. https://medicine.wustl.edu/news/effort-improve-radiation-therapy-veterans-receives-nearly-4-million/; Veteran's Administration. Consultant; Veteran's Administration. Stock; ViewRay Inc. Chair Radiation Oncology Committee; NRG Oncology. Radiation Oncology Practice Assessment; Veterans Affairs. Co-chair GU Steering Committee; NCI.

Send Email for Randall Brenneman


Assets

SU_20_2201 - A Propensity Analysis Comparing Definitive Chemo-Radiation for Muscle-Invasive Adenocarcinoma of the Bladder Versus Urothelial Carcinoma of the Bladder using the National Cancer Database (NCDB)



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for A Propensity Analysis Comparing Definitive Chemo-Radiation for Muscle-Invasive Adenocarcinoma of the Bladder Versus Urothelial Carcinoma of the Bladder using the National Cancer Database (NCDB)